Erdheim-Chester Disease clinical trials

The registry lists 22 studies for Erdheim-Chester Disease across more than 10 countries. 12 are recruiting or about to start. 10 of them are mainly about Erdheim-Chester Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.

Get an email when these change. Save the Erdheim-Chester Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting: 12
Terminated: 3
Active, not recruiting: 2
Completed: 2
Withdrawn: 2
Status unknown: 1

Phase

Phase 2: 8
Phase 1: 3
Phase 3: 2
Early Phase 1: 1

Where

United States: 15
Italy: 5
United Kingdom: 3
France: 3
Germany: 2
China: 2

Who runs them

Memorial Sloan Kettering Cancer Center (4) · Cancer Research UK (2) · Meyer Children's Hospital IRCCS (2) · The Hospital for Sick Children (1) · Ospedale San Raffaele (1) · University of Alabama at Birmingham (1) · National Human Genome Research Institute (NHGRI) (1) · Groupe Hospitalier Pitie-Salpetriere (1)

What is being tested here

Drugs under test in Erdheim-Chester Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cobimetinib	2	1	2
Dabrafenib	1	1	2
Trametinib	1	1	1
68Ga-pentixafor	1	0	1
Vemurafenib	1	1	1
Adrixetinib	1	0	1
Lenalidomide	0	0	1
BRAF V600E Inhibitor HLX208	0	0	1
Bevacizumab	0	0	1
Temsirolimus	0	0	1

Coming up

2phase 3 studies under way

4studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4

Jun 2027Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases · Memorial Sloan Kettering Cancer Center
Jul 2027Histiocytic Disorder Follow-up Study · University of Alabama at Birmingham
Oct 2027Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses · Memorial Sloan Kettering Cancer Center
Oct 2027In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET · Memorial Sloan Kettering Cancer Center

Who these studies take

Of the 12 Erdheim-Chester Disease studies recruiting now, 9 (75%) set no upper age limit and 1 (8%) stop at 75 or younger. 7 (58%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.

Recruiting studies that take each age, of 12
Age	Women	Men
10	7 (58%)	7 (58%)
18	12 (100%)	12 (100%)
30	12 (100%)	12 (100%)
40	12 (100%)	12 (100%)
50	12 (100%)	12 (100%)
65	12 (100%)	12 (100%)
75	11 (92%)	11 (92%)
85	11 (92%)	11 (92%)

Across all 22 studies, recruiting or not: 5% stop at 75 or younger and 5% at 65; 45% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 14, 2026.

Results posted1

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseNov 5, 2026NCT01552434

Studies

Recruiting first, then most recently updated. Showing 22 of 22. search them.